Actinogen Medical (ASX:ACW) OCF Margin %: 0.00% (As of Dec. 2025)


What is Actinogen Medical OCF Margin %?

Actinogen Medical ASX:ACW +1.52% OCF Margin % is 0.00% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 959 Biotechnology companies, Actinogen Medical ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Actinogen Medical's Cash Flow from Operations for the six months ended in Dec. 2025 was A$-7.12 Mil. Actinogen Medical's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Actinogen Medical's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Actinogen Medical's current OCF Yield % is -13.07%.

The historical rank and industry rank for Actinogen Medical's OCF Margin % or its related term are showing as below:


ASX:ACW's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Actinogen Medical OCF Margin % Related Terms

Actinogen Medical OCF Margin % Historical Data

* Premium members only.

The historical data trend for Actinogen Medical's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actinogen Medical OCF Margin % Chart

Actinogen Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Actinogen Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Actinogen Medical OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Actinogen Medical's OCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-7.556/0
= %

Actinogen Medical's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-7.118/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Actinogen Medical (ASX:ACW) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Actinogen Medical and its competitors. According to the industry distribution chart, Actinogen Medical ranks #999999 out of 959 companies in the Biotechnology industry.
Is Actinogen Medical's OCF Margin % too high?
Actinogen Medical's current OCF Margin % is 0.00%. Based on the distribution chart, Actinogen Medical ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Actinogen Medical's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Actinogen Medical ranks #999999 out of 959 companies for OCF Margin %. This places Actinogen Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Actinogen Medical and its competitors. Actinogen Medical's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actinogen Medical stock overvalued right now?
Actinogen Medical (ASX:ACW) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Actinogen Medical (ASX:ACW), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actinogen Medical Business Description

Other Exchanges ATGGF:USA3AC:Germany
Address 109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000
Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.